XML 75 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized $ 44,032   $ 33,174 $ 111,320 $ 248,603
Drug Product Revenue [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized 686     8,924  
Astellas Agreement [Member] | Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Changes in revenue due to prior period adjustment of performance obligations 100        
Astellas Agreement [Member] | Drug Product Revenue [Member] | Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Changes in revenue due to prior period adjustment of performance obligations 4,000        
Drug product revenue recognized   $ 8,200      
AstraZeneca Agreements [Member] | Drug Product Revenue [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized 4,643     $ 4,643  
AstraZeneca Agreements [Member] | Drug Product Revenue [Member] | U.S./RoW [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized $ 4,600